Yaron Naos - Sep 7, 2022 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role: Sr. VP, Operations
Signature: /s/ Eyal Rubin, POA
Stock symbol: PLX
Transactions as of: Sep 7, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/9/2022, 05:04 PM
Next filing: Aug 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLX	Stock Options (Right to Buy)	Award	$0	+340K		$0.00	340K	Sep 7, 2022	Common Stock	340K	$1.03	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
F2	Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025, (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028 and (iii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030.

Content

The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.

Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025, (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028 and (iii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030.